A 52-week study to assess the safety and efficacy of Dexpramipexole, an oral eosinophil lowering therapy, in adolescents and adults with Severe Eosinophilic Asthma (GINA steps 4 and 5).
A 52-week study to assess the safety and efficacy of Dexpramipexole, an oral eosinophil lowering therapy, in adolescents and adults with Severe Eosinophilic Asthma (GINA steps 4 and 5).
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
